Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.
about
Treatment and prophylaxis of invasive candidiasisNeonatal candidiasis: diagnosis, prevention, and treatmentPharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyCommentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric CasesThe use of antifungal therapy in neonatal intensive care.Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.Considerations in the pharmacologic treatment and prevention of neonatal sepsis.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.Need of voriconazole high dosages, with documented cerebrospinal fluid penetration, for treatment of cerebral aspergillosis in a 6-month-old leukaemic girl.A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in ChildrenInvasive Aspergillosis in Children: Update on Current Guidelines
P2860
Q27001567-B84CC56E-2E4E-497E-955B-5704CAA3558DQ27008471-0BC24887-C66E-4A98-8580-011742FB156FQ33827819-AF6C6561-4178-4F15-B483-D867215B3BD2Q35973357-F44EDFE6-9919-4022-899C-DEADD66A1AD7Q36948094-957DF9CE-C789-455E-95C0-878B4BB17C4AQ36974048-7E7E203C-370C-42A9-B6A8-8163ED3D4F24Q37985070-E6AD0F96-AD6A-4E0F-A506-058E323B340CQ38117791-996B85FC-BEF8-4BA0-9164-2CD64F78FA83Q38161849-0BFF9BE0-3E9D-4701-B8D0-D584B2EABC82Q38193337-E774842E-854C-4BD7-8A51-5594E307B6FEQ38215682-340F9F2F-5CC8-49AB-837C-22C7F359B065Q38880522-C786AA62-5335-4F69-B64C-FF82C48976B4Q39466921-C984D6FC-C922-40C4-9D9F-74DD684066F8Q41444763-127DC3E0-D0D1-43EA-9BAC-64DE3A1A5401Q57730442-25AE9967-D345-42EB-B54B-E168D931889EQ58775551-C52F47DD-1191-4C29-95B2-20D86D911199
P2860
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Therapeutic monitoring of vori ...... ncentrations for ten children.
@ast
Therapeutic monitoring of vori ...... ncentrations for ten children.
@en
type
label
Therapeutic monitoring of vori ...... ncentrations for ten children.
@ast
Therapeutic monitoring of vori ...... ncentrations for ten children.
@en
prefLabel
Therapeutic monitoring of vori ...... ncentrations for ten children.
@ast
Therapeutic monitoring of vori ...... ncentrations for ten children.
@en
P2093
P2860
P1476
Therapeutic monitoring of vori ...... ncentrations for ten children.
@en
P2093
Andrew T Pavia
Anne J Blaschke
Cassandra Moran
Daniel K Benjamin
Elizabeth H Doby
Michael Cohen-Wolkowiez
Paul L Martin
Robert M Ward
Timothy A Driscoll
P2860
P304
P356
10.1097/INF.0B013E31824ACC33
P577
2012-06-01T00:00:00Z